Summit Biosciences Inc.

Form 483 issued February 21, 2025 · Lexington, Kentucky

Inspection
Feb 18 – Feb 21, 2025
Observations
2
Pages
3
FEI number
3007577023

In short: On February 21, 2025, FDA issued a Form 483 with 2 observations to Summit Biosciences Inc. in Lexington, Kentucky (FEI 3007577023) after an inspection that ran Feb 18 – Feb 21, 2025. The investigator was Ucheabuchi C. Chudi-Nwankwor. Most observations concern production; the most-cited regulation is 21 CFR 211.110 (sampling and testing of in-process materials and drug products).

At a glance

Observations span 1 system, led by production.

Production1
Other1

Most cited: FDCA 582(b)(4) (1×) · 211.110(a) (1×)

What FDA observed

Preview: the opening words of each observation
  1. 01
    FDCA 582(b)(4)

    Your firm failed to have systems in place to enable compliance with the verification…

  2. 02

    Written procedures are not established that describe the in-process controls and examinations to be conducted on…

The full 483

Plus the full detail behind each one, exactly as FDA wrote it.

Get the full 483

This inspection in context

Questions about this 483

What did FDA find at Summit Biosciences Inc.?

FDA listed 2 observations on this Form 483, mostly about production. The most-cited regulation is 21 CFR 211.110 (sampling and testing of in-process materials and drug products). The opening words of each observation are shown on this page.

Who inspected Summit Biosciences Inc.?

Ucheabuchi C. Chudi-Nwankwor is named on this Form 483, for the inspection of Feb 18 – Feb 21, 2025. Each investigator has a profile showing what they cite most.

When was Summit Biosciences Inc. inspected by FDA?

The inspection ran Feb 18 – Feb 21, 2025, and the Form 483 is dated February 21, 2025.

How do I get the full Form 483 for Summit Biosciences Inc.?

Download the original PDF from FDA Intel for $99, with no subscription. Your first Form 483 or letter is on us. You also get an invoice PDF with the order.

$99Get it free